Anna Smit, MSc

PhD student
Department of Hematology, Erasmus University Medical Center Cancer Institute
Rotterdam, Zuid-Holland, Netherlands

Anna Smit, MSc, is a PhD student at Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands, specializing in innovative clinical trial design in multiple myeloma. Her research focuses on the use of minimal residual disease (MRD) as a prognostic tool and surrogate endpoint, the use of real-world data (RWD) and trial design.

Disclosure information not submitted.

Presentation(s):

• (OA-62) Dynamic Prediction of Progression Based on Minimal Residual Disease (MRD) in Patients with Newly Diagnosed Transplant Eligible Multiple Myeloma

  Thursday, September 18, 2025
  15:08 - 15:16 East Coast USA Time

• Regulatory Session

  Friday, September 19, 2025
  16:30 - 16:40 East Coast USA Time

• Panel Discussion

  Friday, September 19, 2025
  16:40 - 17:20 East Coast USA Time